Section: 
Rhinology issues
Rhinology issuesAssessment of quality of life in patients with chronic rhinosinusitis with nasal polyps and asthma under biological therapy
D. A. Sivokhin (1), V. M. Svistushkin (2), E. S. Shchennikova (3), E. R. Danelyan (4), N. P. Knyazheskaya (5), A. A. Kameleva (6)
(1), (2), (3), (4) Sechenov First Moscow State Medical University (Sechenov University), Moscow, 119991, Russian Federation, (5) Pirogov Russian National Research Medical University, Moscow, 117997, Russian Federation, (6) Yudin City Clinical Hospital of Moscow Healthcare Departmen, Moscow, 105077, Russian Federation, (6) Russian University of Peoples’ Friendship, Moscow, 117198, Russian Federation
UDK: УДК 616.216-002-006.5+616.48]-056.2-092.11:316.728:615.34
DOI: https://doi.org/10.18692/1810-4800-2025-2-57-64
ABSTRACT
Abstract. Introduction. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is predominantly a type 2 inflammation-mediated disease characterized by numerous symptoms that significantly reduce quality of life. In recent years, biological therapy for the treatment of CRSwNP and asthma has dramatically changed the approach to managing these diseases, allowing a significant improvement of the condition of patients. Objective. To determine the dynamics of the most common symptoms affecting patients with CRSwNP and comorbid asthma during biological therapy with dupilumab, depending on the previously used surgical treatment. Patients and Methods. An observational cohort study was conducted involving 45 patients with PRS and bronchial asthma receiving dupilumab therapy. Patients were divided into 3 groups of 15 people: Group 1: patients without a history of surgical interventions associated with the removal of polyps from the nasal cavity and paranasal sinuses, Group 2: patients with a history of a single surgical intervention, Group 3: patients who have undergone 2 or more surgical interventions. Symptoms (nasal congestion, mucous discharge, mucus drip, facial pressure, decreased sense of smell, headache, fatigue, sleep quality) were assessed using VAS before treatment and at 1, 2, 4, 16, and 52 weeks of therapy. Results. In all cases, patients noted a significant improvement in all studied symptoms. However, patients in Group 1 showed the fastest regression of complaints related to nasal congestion, mucous discharge, postnasal drip, sleep disturbances, and frequent awakenings (p ≤ 0.05). The average time for the restoration of the sense of smell after starting biological therapy was 17 days, with only two patients not experiencing the return of smell after one year of treatment. Conclusion. In patients with severe CRSwNP and comorbid asthma, biological therapy with dupilumab reduced the severity of CRSwNP symptoms by more than twofold within one month of treatment. The earliest effect was observed in patients in Group 1.
Publication date:
21.04.2025
Keywords:
chronic rhinosinusitis with nasal polyps, CRSwNP, biological therapy, dupilumab, quality of life, nasal polyps, paranasal sinuses, type 2 inflammation, asthma, aspirin-exacerbated respiratory disease, Samter’s triad For citation:
Sivokhin D. A., Svistushkin V. M., Shchennikova E. S., Danelyan E. R., Knyazheskaya N. P., Ka-meleva A. A. Assessment of quality of life in patients with chronic rhinosinusitis with nasal polyps and asthma under biological therapy. Russian Otorhinolaryngology. 2025;24(2):57-64. (In Russ.) https://doi.org/10.18692/1810-4800-2025-2-57-64